Lucas Moreno

Summary

Affiliation: Institute of Cancer Research
Country: UK

Publications

  1. doi request reprint Long-term follow-up of children with high-risk neuroblastoma: the ENSG5 trial experience
    Lucas Moreno
    Children and Young People s Unit, The Royal Marsden NHS Foundation Trust The Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Pediatr Blood Cancer 60:1135-40. 2013
  2. doi request reprint How can attrition rates be reduced in cancer drug discovery?
    Lucas Moreno
    Paediatric Drug Development, Children and Young People s Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton SM2 5PT, UK 44 0 208 661 3678 44 0 208 661 3617
    Expert Opin Drug Discov 8:363-8. 2013
  3. ncbi request reprint Preclinical drug development for childhood cancer
    Lucas Moreno
    The Royal Marsden NHS Foundation Trust, Children and Young People s Unit, Sutton, Surrey, UK
    Expert Opin Drug Discov 6:49-64. 2011
  4. ncbi request reprint Toxicity and outcome of children and adolescents participating in phase I/II trials of novel anticancer drugs: the Royal Marsden experience
    Daniel A Morgenstern
    Pediatric Drug Development Unit, Children and Young People s Unit, The Royal Marsden NHS Foundation Trust Pediatric Drug Development Team, Divisions of Cancer Therapeutics and Clinical Studies, The Institute of Cancer Research, Sutton Pediatric Oncology Department, Great Ormond Street Hospital Institute of Child Health, University College London, London, UK
    J Pediatr Hematol Oncol 36:218-23. 2014
  5. ncbi request reprint MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistance
    Giuseppe Barone
    The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, United Kingdom
    Curr Drug Targets 15:114-23. 2014

Collaborators

Detail Information

Publications5

  1. doi request reprint Long-term follow-up of children with high-risk neuroblastoma: the ENSG5 trial experience
    Lucas Moreno
    Children and Young People s Unit, The Royal Marsden NHS Foundation Trust The Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Pediatr Blood Cancer 60:1135-40. 2013
    ..The aim of this study was to identify the nature and severity of late complications of metastatic neuroblastoma survivors included in the ENSG5 clinical trial...
  2. doi request reprint How can attrition rates be reduced in cancer drug discovery?
    Lucas Moreno
    Paediatric Drug Development, Children and Young People s Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton SM2 5PT, UK 44 0 208 661 3678 44 0 208 661 3617
    Expert Opin Drug Discov 8:363-8. 2013
    ..Finally, there is a need for increased collaboration to combine the unique strengths between industry, academia and regulators to ensure that the needs of all stakeholders are met...
  3. ncbi request reprint Preclinical drug development for childhood cancer
    Lucas Moreno
    The Royal Marsden NHS Foundation Trust, Children and Young People s Unit, Sutton, Surrey, UK
    Expert Opin Drug Discov 6:49-64. 2011
    ..More effective drugs are needed to treat poor prognosis paediatric malignancies. Development of anticancer agents for childhood cancers faces several unique challenges compared with their adult counterparts...
  4. ncbi request reprint Toxicity and outcome of children and adolescents participating in phase I/II trials of novel anticancer drugs: the Royal Marsden experience
    Daniel A Morgenstern
    Pediatric Drug Development Unit, Children and Young People s Unit, The Royal Marsden NHS Foundation Trust Pediatric Drug Development Team, Divisions of Cancer Therapeutics and Clinical Studies, The Institute of Cancer Research, Sutton Pediatric Oncology Department, Great Ormond Street Hospital Institute of Child Health, University College London, London, UK
    J Pediatr Hematol Oncol 36:218-23. 2014
    ..Continued expansion of the portfolio is needed ultimately to improve the outcomes for those with resistant disease. ..
  5. ncbi request reprint MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistance
    Giuseppe Barone
    The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, United Kingdom
    Curr Drug Targets 15:114-23. 2014
    ..In conclusion, targeting the interaction between p53 and its main negative regulator MDM2 represents a major new therapeutic approach in poor prognosis paediatric malignancies without p53 mutations. ..